Have a personal or library account? Click to login
Clinical features and immunohistochemistry profile of biopsy-proven gastric gastrointestinal stromal tumor (GIST): a description of 5 years case series and literature review of GIST Cover

Clinical features and immunohistochemistry profile of biopsy-proven gastric gastrointestinal stromal tumor (GIST): a description of 5 years case series and literature review of GIST

Open Access
|Sep 2020

References

  1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23:70–83.
  2. Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc’h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PloS One. 2011; 6:e20294.
  3. El-Menyar A, Mekkodathil A, Al-Thani H. Diagnosis and management of gastrointestinal stromal tumors: an up-to-date literature review. J Can Res Ther. 2017; 13:889–900.
  4. Bamboat ZM, Dematteo RP. Updates on the management of gastrointestinal stromal tumors. Surg Oncol Clin N Am. 2012; 21:301–16.
  5. Yan BM, Kaplan GG, Urbanski S, Nash CL, Beck PL. Epidemiology of gastrointestinal stromal tumors in a defined Canadian Health Region: a population-based study. Int J Surg Pathol. 2008; 16:241–50.
  6. Wang ZH, Liang XB, Wang Y, Ma GL, Qu YQ, Tian XW. [Epidemiology survey of gastrointestinal stromal tumor in Shanxi Province in 2011]. Zhonghua yi xue za zhi. 2013; 93:2541–4.
  7. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Can. 2002; 38(Suppl 5):S39–51.
  8. Kramer K, Knippschild U, Mayer B, Bogelspacher K, Spatz H, Henne-Bruns D, et al. Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC Cancer. 2015; 15:57.
  9. Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastro Oncol. 2017; 8:466.
  10. Ucar AD, Oymaci E, Carti EB, Yakan S, Vardar E, Erkan N, et al. Characteristics of Emergency Gastrointestinal Stromal Tumor (GIST). Hepatogastroenterology. 2015; 62:635–40.
  11. Caterino S, Lorenzon L, Petrucciani N, Iannicelli E, Pilozzi E, Romiti A, et al. Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. World J Surg Oncol. 2011; 9:13.
  12. Sorour MA, Kassem MI, Ghazal Ael H, El-Riwini MT, Abu Nasr A. Gastrointestinal stromal tumors (GIST) related emergencies. Int J Surg. 2014; 12:269–80.
  13. Luo J-M, Cao F-L, Meng C, Lin L-J, Ma S-Q, Peng S-H, et al. Clinicopathological and molecular characteristics of synchronous gastric adenocarcinoma and gastrointestinal stromal tumors. Sci Rep. 2017; 7:12890.
  14. Raza MA, Shahab AS, Mazzara P. Gastrointestinal stromal tumors: association with Helicobacter pylori gastritis. Am J Clin Pathol. 2012; 138:A351.
  15. Gopie P, Mei L, Faber AC, Grossman SR, Smith SC, Boikos SA. Classification of gastrointestinal stromal tumor syndromes. Endocr Relat Cancer. 2018; 25:R49–58.
  16. Emile JF, Théou N, Tabone S, Cortez A, Terrier P, Chaumette MT, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol. 2004; 2:597–605.
  17. Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv. 2001; 438:1–12.
  18. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299:708–10.
  19. Wang JH, Lasota J, Miettinen M. Succinate dehydrogenase subunit B (SDHB) is expressed in neurofibromatosis 1-associated gastro-intestinal stromal tumors (GISTs): implications for the SDHB expression based classification of GISTs. J Can. 2011; 2:90.
  20. Bajor J. Gastrointestinal stromal tumours in patients with type 1 neurofibromatosis. Clin Exp Med J. 2009; 3:247–54.
  21. Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010; 57:259–70.
  22. Yang ML, Wang JC, Zou WB, Yao DK. Clinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients. Oncol Lett. 2018; 16:4905–14.
  23. Lim KT, Tan KY. Current research and treatment for gastrointestinal stromal tumors. World J Gastroenterol. 2017; 23:4856.
  24. Maki RG. Gastrointestinal stromal tumors (GIST) and their management. Gastrointest Cancer Res. 2007; 1(4 Suppl 2):S81.
  25. Lanke G, Lee JH. How best to manage gastrointestinal stromal tumor. World J Clin Oncol. 2017; 8:135.
  26. Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol. 2018; 24:2806.
  27. Din OS, Woll PJ. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag. 2008; 4:149.
DOI: https://doi.org/10.1515/abm-2020-0017 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Language: English
Page range: 111 - 117
Published on: Sep 10, 2020
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2020 Chuthamas Ongprakobkul, Pakkapon Rattanachaisit, Nachchakorn Kwankajonwong, Duangporn Werawatganon, Naruemon Klaikaew, Rungsun Rerknimitr, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.